Search for Elan Corp PLC and
  1. January 15, 2014

    Trial hears doctor ‘flabbergasted’ by Martoma’s drug knowledge

    A doctor briefed on a confidential Alzheimer’s drug trial testified on Wednesday that he was “flabbergasted” that Mathew...

  2. January 5, 2014

    Former SAC manager resolute as trial poised to start

    When prosecutors open their trial this week against Mathew Martoma, a former SAC Capital portfolio manager accused of...

  1. August 25, 2013

    Amgen’s $10.5bn takeover of Onyx approved by both boards

    Amgen said on Sunday night that its takeover of Onyx, the US cancer drug developer, at $125 a share had been approved by...

  2. August 2, 2013

    Better ways to play the merger mania

    Mega mergers are back. This week, advertising groups Omnicom and Publicis announced a $35bn tie-up. Just a day or two...

  3. July 30, 2013

    US biotech stocks ride wave of investor euphoria

    Biotechnology companies are raising money at the fastest rate since the dotcom boom, underscoring the renewed appetite for...

  4. July 29, 2013

    Publicis gains as ‘merger of equals’ buoys European media

    Shares in Publicis, the French advertising agency that has plans to merge with US rival Omnicom, climbed as bid news helped...

  5. July 29, 2013

    Deals fail to lift US stocks

    Deal news was responsible for the two biggest movers on the S&P 500 on Monday, as advertising company Interpublic Group led...

  6. July 29, 2013

    Perrigo / Elan: tax shopping

    Remember the quaint old days, when mergers aimed for cost savings? Ah, the deals of yesteryear. It is all about taxes now....

  7. FT Alphaville

    July 29, 2013

    The (early) Lunch Wrap

    Good morning New York, FT ALPHAVILLE And Shibor’s off again… Izzy notes another pick up in Shibor and wonders if there might...

  8. July 29, 2013

    Perrigo to buy Elan for $8.6bn as it eyes aid of Irish tax system

    Perrigo has agreed to buy Ireland-based Elan Corp for $8.6bn in a cash-and-shares deal that will provide the US generic...

  9. July 28, 2013

    GLG strategy feeds off ‘fear and greed’ in equity markets

    GLG Partners’ Pierre Lagrange has increased his gross exposure to the equity market as his conviction about a positive...

  10. FT Alphaville

    July 19, 2013

    "Edge", SEC v Steve Cohen edition

    Friday was a very very hot day on the East Coast. We wonder if they’re staying cool on SAC’s trading floor this afternoon…...

  11. June 27, 2013

    Ireland’s Green Reit seeks to raise €200m

    Green Reit, a newly established Irish property company, is planning to raise €200m in a flotation on the Dublin and London...

  12. June 21, 2013

    Bid talk lifts Nokia and Kabel amid European equity losses

    Losses for financial stocks and carmakers were at the heart of European equity market weakness this week but bid speculation...

  13. June 20, 2013

    Bid talk gives battered stocks a touch of Elan

    Snippets of merger talk emerged to provide slight relief from the heavy selling in European stocks seen across all markets...

  14. June 20, 2013

    Disney lower as Fed fallout hits US stocks

    Walt Disney shares fell 3.7 per cent to $61.98 after Goldman Sachs removed the stock from its “conviction buy” list, reports...

  15. June 18, 2013

    Elan / Royalty Pharma: time out

    Just as the fat lady was about to sing, her microphone got switched off. That is the outcome, for the moment, of Royalty...

  16. June 18, 2013

    Royalty Pharma abandons bid for Elan

    Royalty Pharma has abandoned its hostile $8bn bid for Elan, leaving the future of the Irish pharmaceutical group unclear...

  17. June 17, 2013

    Elan shareholders support buyback

    Royalty Pharma’s $6.7bn hostile bid for Elan was set to lapse on Monday after shareholders created a stalemate, by approving...

  18. June 14, 2013

    Elan opens formal sale process

    Elan, the Irish pharmaceutical business facing a $6.7bn hostile bid from Royalty Pharma, said on Friday it was putting...

  19. June 13, 2013

    Royalty suffers setback in Elan poll

    Royalty Pharma’s hostile $6.7bn takeover for Dublin-based Elan received a sharp setback on Thursday as the US group’s...

  20. June 13, 2013

    Italian banks lead Eurofirst recovery

    Turbulence in Europe’s equity markets kept investors on their toes as sharp opening losses gave way in afternoon trade, with...

  21. June 13, 2013

    Elan/Royalty Pharma: drug war

    Talk about missing the wood for the trees. Royalty Pharma’s hostile takeover attempt for Dublin-based Elan Corp looks to be...

  22. June 11, 2013

    Royalty accuses Elan of misleading shareholders over vote

    Royalty Pharma has accused Dublin-based Elan of misleading shareholders over voting procedures pivotal to its $6.7bn hostile...

  23. June 11, 2013

    Lombard: IAG fails to electrify with promise of jam tomorrow

    “O’er the wires the electric message came – he is no better, he is much the same!” The words of rotten Victorian poet Alfred...

  24. June 10, 2013

    Elan boosted by talk of counterbid

    Gains for a number of drugmakers and engineering companies helped ensure the fall on the pan-European index was kept to a...

  25. June 7, 2013

    Royalty Pharma raises Elan offer

    The bitter battle for Elan intensified on Friday after private equity group Royalty Pharma raised its all-cash offer for the...

  26. June 4, 2013

    Elan turns to courts to block hostile bid from Royalty Pharma

    Elan, the Irish-based speciality drug company, claimed its shareholders would be drawn into a “shadowy web of hedge funds”...

  27. May 31, 2013

    Elan / Royalty Pharma: number crunchers

    Every takeover should be finally decided on the basis of valuation. So the battle between Royalty Pharma and Elan Corp could...

  28. May 27, 2013

    Biotech: it’s back

    If you are an investor in Celgene you can stop reading now. You are already on your own private island, bought with some of...

  29. May 24, 2013

    European lenders unloved amid growth fears

    European markets reversed much of their May gains this week as investors sold out of equities amid global growth concerns....

  30. May 20, 2013

    Elan steps up fight against Royalty Pharma bid

    Royalty Pharma, the US private equity group, stepped up the pressure on Elan with an improved $12.50-a-share cash offer,...

  31. May 16, 2013

    Elan rejects Royal Pharma’s $5.7bn bid

    Elan, the Irish drug company, has formally rejected as “grossly inadequate” Royalty Pharma’s $5.7bn takeover bid. Elan also...

  32. May 13, 2013

    Elan: two can play

    Sometimes, imitation is not meant to be the sincerest form of flattery. In its attempt to escape the clutches of Royalty...

  33. May 13, 2013

    Elan seeks to weaken hostile bid with $1bn Theravance deal

    Elan, the Irish drug company facing a hostile bid from Royalty Pharma, plans to pay $1bn to buy the rights for four...

  34. April 19, 2013

    Letter from Lex – merger Monday

    Merger Monday they called it this week, and you could hear the mergers and acquisitions bankers squealing with joy. First...

  35. April 18, 2013

    Elan reveals results of $1bn share buyback

    Elan, the Irish drug company at the centre of a hostile takeover bid, announced the results of a share buyback that some...

  36. April 15, 2013

    Elan / Royalty Pharma: win-win

    Here is a good one for the textbooks. Company A reckons that discovering and producing drugs is a mug’s game. Too many...

  37. April 15, 2013

    Royalty Pharma raises offer for Elan

    Royalty Pharma has increased its offer for Elan , the Irish pharmaceutical business, to up to $12 a share with the launch of...

  38. April 10, 2013

    BofA hires ex-Goldman partner in M&A role

    Bank of America Merrill Lynch has hired former Goldman Sachs banker Luigi Rizzo to lead its mergers and acquisitions...

Search for Elan Corp PLC and

RELATED VIDEOS

Videos from FT.com that closely match this topic

  1. Lex discusses what is at stake in takeover saga...
    June 13, 2013

    Lex discusses what is at stake in takeover saga

  2. Lex on Royalty Pharma's $6.6bn indicative bid for Elan...
    February 25, 2013

    Lex on Royalty Pharma's $6.6bn indicative bid for Elan